发明授权
US08691762B2 Methods and assays for treating subjects with SHANK3 deletion, mutation or reduced expression
有权
用SHANK3缺失，突变或降低表达治疗受试者的方法和测定法
- 专利标题： Methods and assays for treating subjects with SHANK3 deletion, mutation or reduced expression
- 专利标题（中）： 用SHANK3缺失，突变或降低表达治疗受试者的方法和测定法
-
申请号： US13425633申请日： 2012-03-21
-
公开(公告)号： US08691762B2公开(公告)日： 2014-04-08
- 发明人: Joseph Buxbaum , Takeshi Sakurai , Ozlem Gunal
- 申请人： Joseph Buxbaum , Takeshi Sakurai , Ozlem Gunal
- 申请人地址： US NY New York
- 专利权人： Mount Sinai School of Medicine
- 当前专利权人： Mount Sinai School of Medicine
- 当前专利权人地址： US NY New York
- 代理机构： Amster, Rothstein & Ebenstein LLP
- 主分类号： A61K38/30
- IPC分类号： A61K38/30
摘要：
Methods and assays are disclosed for treating subjects with 22q13 deletion syndrome or SHANK3 deletion or duplication, mutation or reduced expression, where the methods comprise administering to the subject insulin-like growth factor 1 (IGF-1), IGF-1-derived peptide or analog, growth hormone, an AMPAkine, a compound that directly or indirectly enhances glutamate neurotransmission, including by inhibiting inhibitory (most typically GABA) transmission, or an agent that activates the growth hormone receptor or the insulin-like growth factor 1 (IGF-1) receptor, or a downstream signaling pathway thereof.
公开/授权文献
信息查询
IPC分类:
